Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 167 | uM | 7536.068 | 0.5677 | -0.1724 | 0.6416 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.0000853 | uM | 7537.069 | 0.9338 | 0.9319 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7537.069 | 0.9462 | 0.9448 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7537.069 | 0.9336 | 0.9317 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7537.069 | 0.9016 | 0.8979 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7537.069 | 0.8113 | 0.7993 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 0.267 | uM | 7537.069 | 0.8488 | 0.8409 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 1.33 | uM | 7537.069 | 0.9073 | 0.9040 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 6.67 | uM | 7537.069 | 0.8132 | 0.8014 | 1.9773 | |
| SUM229PE | TNBC | - | Sirolimus | MTOR | MTOR | 33.3 | uM | 7537.069 | 0.1817 | -0.1558 | 1.9773 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7538.068 | 0.7188 | 0.3374 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7538.068 | 0.7334 | 0.3704 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7538.068 | 0.4989 | -0.1433 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7538.068 | 0.6158 | 0.1075 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 0.267 | uM | 7538.068 | 0.5410 | -0.0543 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 1.33 | uM | 7538.068 | 0.5181 | -0.1029 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 6.67 | uM | 7538.068 | 0.4934 | -0.1547 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 33.3 | uM | 7538.068 | 0.4510 | -0.2424 | 0.8203 | |
| SUM44PE | HER2amp | Luminal | Sirolimus | MTOR | MTOR | 167 | uM | 7538.068 | 0.5354 | -0.0662 | 0.8203 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 0.000427 | uM | 7540.068 | 0.7016 | 0.3868 | 0.9679 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 0.00213 | uM | 7540.068 | 0.5504 | 0.0791 | 0.9679 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 0.0107 | uM | 7540.068 | 0.5360 | 0.0500 | 0.9679 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 0.0533 | uM | 7540.068 | 0.4248 | -0.1743 | 0.9679 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 0.267 | uM | 7540.068 | 0.4706 | -0.0820 | 0.9679 | |
| SUM52PE | HR+ | Luminal | Sirolimus | MTOR | MTOR | 1.33 | uM | 7540.068 | 0.4334 | -0.1569 | 0.9679 |